

Directions: Take 1 tablet daily

## Atopic Dermatitis Patient Enrollment and Prescription Form

ePrescribe to our pharmacy at "GENTRY HEALTH SERVICES" in Avon Lake, Ohio. P: 1-844-443-6879 F: 1-844-329-2447 PATIENT INFORMATION PRESCRIBER INFORMATION Prescriber's Name Practice Name Weight \_\_\_\_\_ Height \_\_\_\_\_ Phone \_\_\_ Address Address City, State, Zip \_\_\_\_\_ City, State, Zip \_\_\_\_\_ Cell Phone E-Mail Phone \_\_\_\_\_ PLEASE PROVIDE COPY OF PATIENT'S PRESCRIPTION INSURANCE CARD WITH ENROLLMENT FORM Office Contact Person \_\_\_\_ Insurance Co. Name Office Contact EMAIL \_\_\_\_\_ Group# \_\_\_\_ Date Needed Insurance Co. Phone \_\_\_ Prescription Date With my signature on this form. Lalso authorize use of Gentry Health's Services Policy Holder Name \_ which includes serving as my prior authorization designated agent in dealing with Policy Holder Employer medical and prescription insurance companies, and co-pay assistance foundations. Prescriber Signature \_\_\_\_\_ Relationship to Patient Ship to: □Patient □Prescriber's Office □Discount Drug Mart ID# RxBIN PCN PLEASE PROVIDE ALL RELEVANT CHART NOTES FOR INSURANCE PURPOSES Medical Information (DO NOT COMPLETE IF CHART NOTES ARE PROVIDED) Diagnosis \_ \_\_\_ ICD-10 Code \_\_ Date of Diagnosis \_\_\_\_\_\_ Body Surface Affected: ☐ Patient has moderate to severe atopic dermatitis (AD) that is inadequately controlled on prior or current topical therapy Drug Allergies Failed Prior therapies? □ Topical Corticosteroids: □ Topical therapy not appropriate Reason: □ Systemic Corticosteriods, Immunosupressants and/or Phototherapy: Affected Areas: ☐ Hands ☐ Feet □ Scalp □ Groin □ Nails □ Face ☐ Systemic corticosteroids not appropriate ☐ Immunosuppressants not appropriate Other: Phototherapy not appropriate Does the patient have history of conjunctivitis or keratitis? □YES □NO Additional Comments (please indicate days supply if different than suggested days supply) PRESCRIPTION INFORMATION ☐ Adbry® (tralokinumab-ldrm) □ 150mg Pre-filled Syringe ☐ 300 mg Auto-Injector □ ADULT DOSING: \_600MG SQ at week 0 and 300MG every other week Quantity: \_\_\_\_\_ Refills □ PEDIATRIC DOSING: 300MG at week 0 and 150MG every other week Quantity: \_\_\_\_\_ Refills ☐ Cibinqo<sup>TM</sup>(abrocitinib) ☐ 50mg Tablet ☐ 100 mg Tablet 200 mg Tablet Qty: 30 tablets Refills Directions: Take 1 tablet daily □Dupixent® (dupilumab) □ Syringe □ Pen □ ADULT STARTER: \_\_600MG SQ at week 0, 300MG SQ at weeks 2 & 4 \_\_Quantity: \_\_4 Refills \_\_\_\_ \_\_\_ Quantity: \_\_2\_\_\_\_\_ ☐ ADULT MAINTENANCE: 300MG SQ once every 2 weeks Refills ☐ PED (up to 5yr): 200MG SQ every 4 weeks Quantity: 2 Refills \_\_\_\_\_ ☐ PED (up to 5yr): <u>300MG SQ every 4 weeks</u> Quantity: 2 Refills \_\_\_\_\_ Quantity: 2 ☐ PED (6-17 yrs) up to 30kg: <u>600MG\_SQ\_week 0, 300mg\_Q4\_weeks</u> Refills \_\_\_\_\_ ☐ PED (6-17 yrs) up to 60kg: <u>400MG\_SQ\_week 0, 200mg Q2\_weeks</u> Refills Quantity: 2 □ PED (6-17 yrs) above 60kg: <u>600MG\_SQ\_week\_0, 300mg\_Q2\_weeks</u> Quantity: 2 □ EBGLYSS™ (lebrikizumab-lbkz) 250mg/2mL Pre-Filled Syringe 250mg/2mL Pen Refills \_\_\_ □ INITIAL DOSE: <u>500MG SQ at week 0 and week 2</u> Quantity: \_\_\_ □ INDUCTION DOSE: 250 MG SQ every 2 weeks ☐ MAINTENANCE DOSE: 250MG SQ every 4 weeks Refills \_\_\_\_ Quantity: \_\_\_\_\_ OPZELURA™ 1.5% Cream 60 GM Tube Directions: Apply thin layer twice daily to affected areas (up to 20% BSA) MAX 60 gm/wk. Qty: \_\_\_ tube(s) Refills ☐ Rinvoq® (upadacitinib) 15mg ER Tablet □ 30mg ER Tablet

Qty: 30 tablets

Refills